Shuaiji Lu
机构：Shanghai Chest Hospital, Loudi Central Hospital
发表论文 6 篇 · 总被引 89 次 · h-index 4
代表论文
- Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial (2024 · ESMO Open · 被引 44)
- Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial) (2024 · ESMO Open · 被引 34)
- Case report: A rare case of anti-PD-1 sintilimab-induced agranulocytosis/severe neutropenia in non-small cell lung cancer and literature review (2024 · Frontiers in Oncology · 被引 6)
- 132P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC): RATIONALE-307 updated analysis (2022 · Immuno-Oncology Technology · 被引 5)
- Predicting the frequent exacerbator phenotype in COPD: development and validation of a multicenter real-world prediction model (2025 · BMC Medical Informatics and Decision Making)
- 1875P RATIONALE-304: Baseline genetic alterations in tumours with PD-L1 expression ≥50% vs <50% in non-squamous (nsq)-NSCLC treated with first-line tislelizumab (TIS) plus chemotherapy (CT) vs CT alone (2025 · Annals of Oncology)